Skip to content

Tolerance of Surgical Masks in Chronic Respiratory Diseases

Satisfaction Survey on the Tolerability of Surgical Masks for Protection Against the Spread of SARS-CoV2 in Patients With Chronic Respiratory Diseases

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05454631
Acronym
TOLMASK
Enrollment
50
Registered
2022-07-12
Start date
2023-02-06
Completion date
2023-10-30
Last updated
2023-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

breathlessness, face masks, COVID-19, COPD, pulmonary rehabilitation

Brief summary

The study is conducted in the context of the COVID-19 pandemic in general, and more specifically in the context of the evaluation of the use of protective masks as a barrier to the spread of the virus. The wearing of masks is one of the recommended barrier measures to limit the spread of the SARS-CoV-2 virus responsible for COVID-19. It is recommended in all circumstances, and mandatory in some. Regardless of the type of mask used (noting that the so-called surgical masks are by far the most common), there are various disadvantages associated with wearing them. Dyspnoea (unpleasant or upsetting perception of respiratory activity) is one of these disadvantages. It can lead to reluctance to wear the mask, or to the adoption of inappropriate practices that reduce its effectiveness. This side effect of the mask is more pronounced in patients with underlying respiratory diseases. However, not all mask designs are equivalent in terms of their physical properties, which can theoretically generate varying levels of dyspnoea. It is therefore important to determine which mask designs are more or less dyspnogenic, in order to guide the preferential use of certain designs in certain patient categories. The TOLMASK study (Tolerance of SARS-CoV2 Surgical Masks in Patients with Chronic Respiratory Diseases) is a prospective, randomised, triple-blind, single-centre study comparing several surgical masks in a crossover design. The primary objective of the study is to evaluate the respiratory tolerance of different surgical masks and the secondary objective is to evaluate their general tolerance.

Detailed description

The study was conducted in the context of the COVID-19 pandemic in general, and more specifically in the context of the evaluation of the use of protective masks as a barrier to the spread of the virus. The wearing of masks is one of the recommended barrier measures to limit the spread of the SARS-CoV-2 virus responsible for COVID-19. It is recommended in all circumstances, and mandatory in some. Regardless of the type of mask used (noting that the so-called surgical masks are by far the most common), there are various disadvantages associated with wearing them. Dyspnoea (unpleasant or worrying perception of respiratory activity) is one of these disadvantages. It can lead to reluctance to wear the mask, or to the adoption of inappropriate practices that reduce its effectiveness. This side effect of the mask is more pronounced in patients with underlying respiratory diseases. However, not all mask designs are equivalent in terms of their physical properties, which can theoretically generate varying levels of dyspnoea. It is therefore important to determine which mask designs are more or less dyspnogenic, in order to guide the preferential use of certain designs in certain patient categories. The TOLMASK study (Tolerance of SARS-CoV2 Surgical Masks in Patients with Chronic Respiratory Diseases) is a prospective, randomised, triple-blind, single-centre study comparing several surgical masks in a crossover design. The primary objective of the study is to evaluate the respiratory tolerance of different surgical masks and the secondary objective is to evaluate their general tolerance. The inclusion criteria are : 1) patient hospitalised in the respiratory and neuro-respiratory rehabilitation department of the R3S department at the Pitié-Salpêtrière Hospital (Pr Gonzalez-Bermejo); 2) patient enrolled in a respiratory rehabilitation process including exercise training on a cyclo-ergometer or treadmill; 3) hospitalisation in the respiratory rehabilitation department either post-exacerbation of COPD (usual recruitment of the department) or post-COVID (depending on the epidemic situation at the time of the study); 4) patient of age. The criteria for non-inclusion are 1) Exercise re-training under mask ventilatory assistance; 2) Presence of a tracheotomy; 3) Psychiatric disorders (at the discretion of the referring physician); 4) Insufficient command of the French language; 5) Refusal to participate in the study. 50 patients will be included, over a period of 4 months. The duration of participation is 5 days.

Interventions

DEVICEsurgical mask (5 different types)

All the participants will wear 5 different types of surgical mask, in random order.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Masking description

not everyone involved in the research (patients, investigators, caregivers, and statistical analysis stakeholders) will know which mask the patient is using at which time.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient hospitalised in the respiratory and neuro-respiratory SSR service of the R3S department at the Pitié-Salpêtrière Hospital (Pr Gonzalez-Bermejo) * Patient enrolled in a respiratory rehabilitation process including exercise training on a cyclo-ergometer or treadmill * Hospitalization in respiratory rehabilitation unit either in post-exacerbation of COPD * age over 18

Exclusion criteria

* Exercise training under mask ventilation support * Presence of a tracheostomy * Psychiatric disorders (at the discretion of the referring physician) * Insufficient command of the French language * Refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
affective dimension of dyspneaimmediately after a rehabilitation sessionIntensity of the sensory dimension of respiratory discomfort attributed to wearing the mask during exercise training, assessed on an 11-point ordinal scale (from 0, the mask caused no particular respiratory sensation to 10, the mask caused a respiratory sensation as intense as I can imagine)

Secondary

MeasureTime frameDescription
sensory dimension of dyspneaimmediately after a rehabilitation sessionIntensity of the sensory dimension of respiratory discomfort attributed to wearing the mask during exercise training, assessed on an 11-point ordinal scale (from 0, the mask caused no particular respiratory sensation to 10, the mask caused a respiratory sensation as intense as I can imagine)
reliefimmediately after a rehabilitation sessionIntensity of relief on mask removal, rated on an 11-point ordinal scale (from 0, mask removal caused no relief to 10, mask removal caused absolute relief)
MDP (Multidimensional Dyspnea Profile)immediately after a rehabilitation sessionResponse to the Multidimensional Dyspnea Profile questionnaire (French version) The Multidimensional Dyspnoea Profile (MDP) consists of eleven 0-10 numerical rating scales describing the unpleasantness of dyspnea (A1, maximum score of 10), its sensory qualities (5 items \[SQ\], maximum 50), and its emotional qualities (5 items \[A2\], maximum 50).
general comfortimmediately after a rehabilitation sessionOverall comfort of the mask tested, rated on an 11-point ordinal scale (from 0, this mask is horribly uncomfortable, to 10, this mask is perfectly comfortable).
choiceimmediately after a rehabilitation sessionOverall comfort of the mask tested, rated on Choice and ranking of 5 mask disadvantages from a list of 15 In addition, at the end of the study, patients will be asked to indicate which of the masks tested they preferred.

Countries

France

Contacts

Primary ContactThomas SIMILOWSKI, MD
thomas.similowski@aphp.fr+33 (0) 6 69 76 72 52
Backup ContactAntoine GUERDER, MD
antoine.guerder@aphp.fr‭+33 (0) 6 09 04 59 11‬

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026